Biopharmaceutical firm Amgen (AMGN) has just had a major new drug, called “XGEVA,” approved by the FDA.
XGEVA will be used to treat patients with giant cell tumor of bone (GCTB) where surgery presents too many dangers to be a viable option. GCTB often presents itself in individuals between the ages of 20 and 40, and causes fractures in the bones and, if left untreated, can lead to serious complications.
The new drug, which passed the FDA’s rigorous testing, will be administered as an injection to patients, who meet the qualifications, in order to help alleviate and heal the damage done by GCTB.
Amgen shares were up $2.14 or 2.17% at Thursday’s close. The stock is currently 14.3% off of its 52-week highs.
The Bottom Line
Shares of Amgen (AMGN) have a 1.91% yield based on Thursday’s closing price of $98.51.
Amgen (AMGN) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here